Here’€™s why the MCC is reviewing nevirapine (Part 2)
Living with AIDS Programme 92

Home / Health / Here’€™s why the MCC is reviewing nevirapine (Part 2)Living with AIDS Programme 92

It is because of the absence of these documents that the manufacturers of nevirapine ‘€“ Boehringer-Ingelheim ‘€“ withdrew their application for registration of the drug for PMTCT use in the US. Currently, the sponsors of the HIVNET 012 study in Uganda – the National Institutes of Health ‘€“ have returned to that country in an effort to collate the missing documents. In this report, Khopotso Bodibe of Health-e News Service, attempts to piece together why the Uganda study is under review.

To obtain the audio file please contact the Editor.

Author

Support Our Work. Make A Donation

Donate Here!

Free to Share

Creative Commons License

Republish our articles for free, online or in print, under a Creative Commons license.


MOST READ

EDITOR'S PICKS

Newsletter Subscription

Be in the know with our free weekly newsletter. We deliver a round-up of our top stories and insightful reads from across the web.

  • This field is for validation purposes and should be left unchanged.
Enable Notifications OK No thanks